Texto: 
Glucose 132 mg/dL (60-100)
BUN 11 mg/dL (6-16)
Creat 0.6 mg/dL (0.7-1.3)
Na+ 140 mmol/L (138-145)
K 3.1 mmol/L (3.6-5.2)
Cl- 98 mmol/L (98-107)
CO2 28.7 mmol/L (20-28)
Ca 7.9 mg/dL (8.8-10.8)
Ionized Ca 0.87 mmol/L (1.20-1.35)
UA: glucose 250 mg/dL
    ketones 15 mg/dL
    prot neg
UA micro: WBC 5-10 hpf
          RBC 5-10 hpf
          Crystals Ca oxalate
24H UA: 1225 mL, Ca 13 mg/dL, Ca total 159.25 mg/24 hr
Phosphorus 6.2 mg/dL (2.4-4.6)
Mg 1.4 mg/dL (1.6-2.4)
TSH 0.829 mcIU/mL (0.35-4.94)
FT4 1.03 ng/dL (0.70-1.48)
HGB 10.0 g/dL (12.0-16.0)
HCT 31.1 % (36.5-46.0)
1, 25-OH Vit D 41.7 pg/mL (15.9-55.6)
PT 16.3 sec (12.0-14.2)
PTT 31.4 sec (23.7-33.8)
Alk phos 307 units/L (499)
AST 103 units/L (9-26)
ALT 57 units/L (8-30)
Amylase 117 (32-107)
LDH 339 units/L (115-222)
Cortcotpn 67 pg/mL (6-48)
No follow-up imaging specifically indicated for this finding.  Medical management of underlying cause of medullary nephrocalcinosis.
Sagittal ultrasonographic images of the right kidney demonstrate diffusely echogenic pyramids with subtle posterior shadowing.  The size of the right kidney is at the lower limits of normal.  Normal renal contour is observed without evidence of cortical thinning or scarring.
Medullary Nephrocalcinosis
Medullary Nephrocalcinosis caused by:
    Renal Tubular Acidosis, Type I (distal form)
    Hyperparathyroidism (hypercalciuria, hypercalcemia)
    Medullary Sponge Kidney
    Hypercalcemic/Hypercalciuric States
    Papillary Necrosis
    Nephrotoxic Drugs (Amphotericin B)
    Furosemide Treatment of the Newborn
    Chronic Pyelonephritis
    Milk-Alkali Syndrome
    Hypervitaminosis D
Eleven-year-old female with history of hypertension.
The laboratory data is extensive and suggests multiple underlying disorders for this patient who was ultimately diagnosed with autonomous polyglandular disorder, type I.


Keywords: 
\-\ dl\\ ketones\\ 15\\ mg\ \(0\)\
\-\ ca\\ 13\\ mg\ \(0\)\
\-\ mg\\ 1\ \(9\)\
\-\ glucose\\ 250\\ mg\ \(2\)\
\-\ glucose\\ 132\\ mg\ \(0\)\
\-\ 6\\ mg\ \(9\)\
\-\ 4\\ mg\ \(10\)\
\-\ bun\\ 11\\ mg\ \(0\)\
\-\ 9\\ mg\ \(2\)\
\-\ 25\\ mg\ \(12\)\
\-\ 2\\ mg\ \(12\)\
\-\ ionized\\ ca\\ 0\ \(0\)\
\-\ 7\\ mmol\ \(2\)\
\-\ 1\\ mmol\ \(1\)\
\-\ ca\\ 7\ \(0\)\
\-\ 10\\ hpf\\ rbc\\ 5\ \(0\)\
\-\ alk\\ phos\\ 307\\ units\ \(0\)\
\-\ 98\\ mmol\ \(1\)\
\-\ tsh\\ 0\ \(0\)\
\-\ medullary\\ sponge\\ kidney\\ hypercalcemic\ \(0\)\
\-\ ldh\\ 339\\ units\ \(0\)\
\-\ creat\\ 0\ \(0\)\
\-\ ca\\ total\\ 159\ \(0\)\
\-\ ast\\ 103\\ units\ \(0\)\
\-\ alt\\ 57\\ units\ \(0\)\
\-\ 87\\ mmol\ \(1\)\
\-\ 7\\ pg\ \(4\)\
\-\ 24\\ hr\\ phosphorus\\ 6\ \(0\)\
\-\ 140\\ mmol\ \(2\)\
\-\ 0\\ g\ \(23\)\
\-\ suggests\\ multiple\\ underlying\\ disorders\ \(1\)\
\-\ normal\\ renal\\ contour\ \(0\)\
\-\ ft4\\ 1\ \(0\)\
\-\ 4\\ sec\ \(2\)\
\-\ 3\\ sec\ \(6\)\
\-\ 0\ \(11370\)\
\-\ wbc\\ 5\ \(0\)\
\-\ renal\\ tubular\\ acidosis\ \(5\)\
\-\ newborn\\ chronic\\ pyelonephritis\\ milk\ \(0\)\
\-\ k\\ 3\ \(2\)\
\-\ hgb\\ 10\ \(0\)\
\-\ cortcotpn\\ 67\\ pg\ \(0\)\
\-\ 7\ \(4391\)\
\-\ 1\ \(15898\)\
\-\ underlying\\ cause\ \(9\)\
\-\ subtle\\ posterior\\ shadowing\ \(1\)\
\-\ sagittal\\ ultrasonographic\\ images\ \(0\)\
\-\ right\\ kidney\ \(165\)\
\-\ ptt\\ 31\ \(0\)\
\-\ pt\\ 16\ \(0\)\
\-\ observed\\ without\\ evidence\ \(1\)\
\-\ medullary\\ nephrocalcinosis\ \(9\)\
\-\ imaging\\ specifically\\ indicated\ \(1\)\
\-\ hct\\ 31\ \(0\)\
\-\ co2\\ 28\ \(0\)\
\-\ autonomous\\ polyglandular\\ disorder\ \(1\)\
\-\ alkali\\ syndrome\\ hypervitaminosis\ \(0\)\
\-\ 6\ \(5312\)\
\-\ 5\ \(8237\)\
\-\ 4\ \(7367\)\
\-\ 3\ \(8405\)\
\-\ 1225\\ ml\ \(0\)\
\-\ 10\ \(1995\)\
\-\ ultimately\\ diagnosed\ \(1\)\
\-\ old\\ female\ \(547\)\
\-\ oh\\ vit\ \(0\)\
\-\ normal\ \(4026\)\
\-\ ml\ \(261\)\
\-\ medical\\ management\ \(20\)\
\-\ lower\\ limits\ \(3\)\
\-\ laboratory\\ data\ \(14\)\
\-\ furosemide\\ treatment\ \(0\)\
\-\ dl\ \(1707\)\
\-\ distal\\ form\ \(1\)\
\-\ cortical\\ thinning\ \(19\)\
\-\ amylase\\ 117\ \(0\)\
\-\ amphotericin\\ b\ \(0\)\
\-\ 98\ \(285\)\
\-\ 9\ \(4978\)\
\-\ 829\\ mciu\ \(0\)\
\-\ 28\ \(276\)\
\-\ 25\ \(658\)\
\-\ 2\ \(13754\)\
\-\ 16\ \(559\)\
\-\ 15\ \(862\)\
\-\ 03\\ ng\ \(2\)\
\-\ year\ \(4238\)\
\-\ ua\ \(5718\)\
\-\ type\ \(681\)\
\-\ size\ \(626\)\
\-\ scarring\ \(55\)\
\-\ patient\ \(6664\)\
\-\ na\ \(21935\)\
\-\ l\ \(296491\)\
\-\ hypertension\ \(298\)\
\-\ hyperparathyroidism\ \(35\)\
\-\ hypercalciuria\ \(4\)\
\-\ hypercalcemia\ \(21\)\
\-\ history\ \(2609\)\
\-\ follow\ \(2068\)\
\-\ finding\ \(1975\)\
\-\ extensive\ \(203\)\
\-\ eleven\ \(5\)\
\-\ cl\ \(9386\)\
\-\ 94\ \(121\)\
\-\ 8\ \(4289\)\
\-\ 70\ \(283\)\
\-\ 60\ \(445\)\
\-\ 55\ \(215\)\
\-\ 499\ \(2\)\
\-\ 48\ \(260\)\
\-\ 46\ \(157\)\
\-\ 41\ \(200\)\
\-\ 36\ \(281\)\
\-\ 35\ \(305\)\
\-\ 33\ \(225\)\
\-\ 32\ \(250\)\
\-\ 30\ \(631\)\
\-\ 26\ \(318\)\
\-\ 23\ \(337\)\
\-\ 222\ \(7\)\
\-\ 20\ \(2416\)\
\-\ 145\ \(22\)\
\-\ 14\ \(608\)\
\-\ 138\ \(19\)\
\-\ 12\ \(1027\)\
\-\ 115\ \(29\)\
\-\ 107\ \(39\)\
\-\ 100\ \(291\)\
